Genetics of the Acute Response to Oral Semaglutide

NCT05340868 · Recruiting

Last updated 2026-05-28

This clinical trial is studying how people with prediabetes or obesity respond to the medication oral semaglutide by analyzing changes in their blood sugar levels over time.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 1,000 people Planned (estimated).

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2022-09 · est. completion 2025-12

Where 1 site · Poland

What this study is testing ClinicalTrials.gov NCT05340868 ↗

Description as written by the study sponsor.

The study aims to investigate the genetic basis of the response to short-term (3 months) orally administered semaglutide treatment, in terms of improving metabolic parameters, including the hormonal response to a standardized meal, and changes in body composition and liver steatosis. In the study, parameters such as fasting and 2-hour glucose during OGTT, HbA1c, body fat mass, body weight, total cholesterol, HDL and LDL, triglycerides, HOMA-IR, Matsuda Index and liver steatosis will be assessed. All the patients will undergo genome-wide genotyping. Moreover, in a subset of participants, muscle and fat biopsies will be performed, before and after the treatment, and liver, muscle and pancreas fat content will be assessed using MRI.

Treatments tested

Semaglutide Pill also known as Rybelsus Drug

Oral semaglutide treatment

Main thing measured	Glycemic measures - change in HbA1c (%)
Sponsor	Medical University of Bialystok
Conditions studied	PreDiabetes, Prediabetic State, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05340868 ↗